Back to News
Market Impact: 0.25
Lexicon Completes SONATA-HCM Enrollment, Eyes 2027 Sotagliflozin Data
Source: marketbeat.com
Healthcare & BiotechCorporate Guidance & Outlook
Lexicon Pharmaceuticals completed enrollment in its Phase III SONATA-HCM trial evaluating sotagliflozin for hypertrophic cardiomyopathy. Topline trial data are expected in Q1 2027, marking a clinical-development milestone but leaving a lengthy timeline to a potential regulatory catalyst.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.20
Ticker Sentiment
LXRX0.45
More News
- Asian chip stocks slide as disappointing Qualcomm, Arm earnings weigh
- Snap shares fall over 10% on third-quarter earnings miss
- Leonardo raises 2026 order guidance after strong 9-mth performance
- HelloFresh Q3 core profit tops forecasts as marketing cuts hit orders
- Microsoft declines Nscale Texas expansion ahead of $35 bln IPO - report
- Hensoldt Q3 adjusted EBITDA beats forecasts, 2026 sales target raised